Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

Launched by UNIVERSITY OF MARYLAND, BALTIMORE · Jan 4, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at a new imaging technique called metabolic magnetic resonance imaging (MRI) to see if it can be safely used in men who may have prostate cancer. The study aims to understand how well this type of MRI can help in diagnosing prostate cancer by examining how the body processes a special substance during the scan. There will be no randomization or placebo treatment in this trial, meaning that all participants will receive the imaging without comparison to a control group.

To participate, men must be between the ages of 40 and 80 and have some signs suggesting prostate cancer, such as a high PSA level (a blood marker) or an abnormal physical exam. They should also be planning to have a biopsy or surgery for prostate cancer. Participants can expect to undergo an MRI scan with a special contrast agent. However, those who cannot have an MRI or the contrast agent for medical reasons will not be eligible. The study is currently recruiting participants, and it's an important step in exploring new ways to diagnose and understand prostate cancer better.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Age greater than 40 and less than 80 years
• 2. Clinical suspicion or history of prostate cancer reflected by one of the following:
• • PSA \> 4ng/ml
• • Abnormal DRE exam
• • Known tissue diagnosis of prostate cancer from prior workup
• • 3. Patient planning to undergo either a MRI targeted biopsy or radical prostatectomy for prostate cancer workup or treatment
• Exclusion Criteria:
• • 1. Inability to undergo MRI scan
• • 2. Inability to receive IV contrast as per institutional protocol.